Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CodaVax-H1N1
- Development stage
- Phase 1
- Lead developer
- Codagenix
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal, Intramuscular
01
Overview
CodaVax-H1N1 is a universal, live-attenuated influenza vaccine candidate developed by Codagenix. It is engineered using the company's proprietary software-driven codon deoptimization platform, which recodes the viral genome to reduce the efficiency of viral protein synthesis, resulting in a virus that is alive but significantly weakened (attenuated). This synthetic biology approach is designed to elicit a broad and durable immune response, potentially offering protection against multiple strains of influenza beyond the specific H1N1 component. The vaccine has been evaluated in Phase 1 clinical trials for safety, tolerability, and immunogenicity, with studies exploring both intranasal spray and intramuscular injection as routes of administration. The development of CodaVax-H1N1 is supported by a strategic partnership with the Serum Institute of India for manufacturing and global reach.
- Brand names
- CodaVax-H1N1CodaVax-H-1N1CodaVax-H 1N1
- Other names
- CodaVax Influenza Vaccine
02
Targets
Influenza A virus hemagglutinin and neuraminidase antigens of H1N1
Beyond the preview
Go deeper on CodaVax-H1N1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CodaVax-H1N1.